EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial

Masahiro Natsuaki, Hirotoshi Watanabe iD, Takeshi Morimoto iD, Ko Yamamoto iD, Yuki Obayashi iD, Ryusuke Nishikawa iD, Kenji Ando iD, Takenori Domei, Satoru Suwa, Manabu Ogita iD, Tsuyoshi Isawa iD, Hiroyuki Takenaka und 14 weitere

Circulation · 20.02.2024 · 149 (8) · 585-600

DOI: 10.1161/circulationaha.123.066720 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 20.02.2024. Verfasst von Masahiro Natsuaki und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Saga University, Japan (M.N.). Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Thrombosis, Nitrates. Die Arbeit wurde bisher 178-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials. METHODS: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.75 mg/day) monotherapy or to DAPT with aspirin (81–100 mg/day) and prasugrel (3.75 mg/day) after loading of 20 mg of prasugrel in both groups. The coprimary end points were major bleeding (Bleeding Academic Research Consortium 3 or 5) for superiority and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) for noninferiority with a relative 50% margin. RESULTS: The full analysis set population consisted of 5966 patients (no-aspirin group, 2984 patients; DAPT group, 2982 patients; age, 71.6±11.7 years; men, 76.6%; acute coronary syndrome, 75.0%). Within 7 days before randomization, aspirin alone, aspirin with P2Y12 inhibitor, oral anticoagulants, and intravenous heparin infusion were given in 21.3%, 6.4%, 8.9%, and 24.5%, respectively. Adherence to the protocol-specified antiplatelet therapy was 88% in both groups at 1 month. At 1 month, the no-aspirin group was not superior to the DAPT group for the coprimary bleeding end point (4.47% and 4.71%; hazard ratio, 0.95 [95% CI, 0.75–1.20]; P superiority =0.66). The no-aspirin group was noninferior to the DAPT group for the coprimary cardiovascular end point (4.12% and 3.69%; hazard ratio, 1.12 [95% CI, 0.87–1.45]; P non inferiority =0.01). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. There was an excess of any unplanned coronary revascularization (1.05% and 0.57%; hazard ratio, 1.83 [95%CI, 1.01–3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) in the no-aspirin group compared with the DAPT group. CONCLUSIONS: The aspirin-free strategy using low-dose prasugrel compared with the DAPT strategy failed to attest superiority for major bleeding within 1 month after PCI but was noninferior for cardiovascular events within 1 month after PCI. However, the aspirin-free strategy was associated with a signal suggesting an excess of coronary events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionThrombosisNitratesMaleHumansMiddle AgedAgedAged, 80 and overPlatelet Aggregation InhibitorsPrasugrel HydrochlorideDrug Therapy, CombinationAspirinHemorrhageStentsTreatment Outcome

Stichwörter der Autor:innen

aspirindual anti-platelet therapypercutaneous coronary intervention

Substanzen

N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterPlatelet Aggregation InhibitorsPrasugrel HydrochlorideAspirinNitrates

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
  • Division of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan (H.W., H.T., T.Y., T.K.).
  • Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M.).
  • Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan (K.Y., K.A., T.D.).
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y. Obayashi, R.N., K.O.).
  • Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan (S.S., M.O.).

ORCID-Profile: Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Kenji Ando, Manabu Ogita, Tsuyoshi Isawa, Tetsuya Ishikawa, Kohei Wakabayashi, Yuko Onishi, Kiyoshi Hibi, Kazuya Kawai, Ruka Yoshida, Gaku Nakazawa, Itsuro Morishima, Koh Ono, Takeshi Kimura

Zitieren

APA

Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Domei, T., Suwa, S., Ogita, M., Isawa, T., Takenaka, H., Yamamoto, T., Ishikawa, T., Hisauchi, I., Wakabayashi, K., Onishi, Y., Hibi, K., Kawai, K., …, & Kimura, T. (2024). An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation, 149(8), 585-600. https://doi.org/10.1161/circulationaha.123.066720

Vancouver

Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation. 2024;149(8):585-600. doi:10.1161/circulationaha.123.066720

BibTeX
@article{Natsuaki2024,
  author = {Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Yamamoto, Ko and Obayashi, Yuki and Nishikawa, Ryusuke and Ando, Kenji and Domei, Takenori and Suwa, Satoru and Ogita, Manabu and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Yamamoto, Takashi and Ishikawa, Tetsuya and Hisauchi, Itaru and Wakabayashi, Kohei and Onishi, Yuko and Hibi, Kiyoshi and Kawai, Kazuya and Yoshida, Ruka and Suzuki, Hiroshi and Nakazawa, Gaku and Kusuyama, Takanori and Morishima, Itsuro and Ono, Koh and Kimura, Takeshi},
  title = {An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {8},
  pages = {585--600},
  doi = {10.1161/circulationaha.123.066720}
}
Kostenlos starten →